Medexus Pharmaceuticals Q3 Earnings Call Highlights

Core Insights - Medexus Pharmaceuticals reported a total net revenue of $25.3 million in fiscal Q3 2026, down from $30.0 million year-over-year, with adjusted EBITDA declining to $4.5 million [5][14][16] - The company highlighted the commercial launch of GRAFAPEX, with product-level net revenue of $2.0 million in Q3 2026 and expectations for it to contribute positively to operating cash flow starting in fiscal Q4 2026 [1][3][6] - Management indicated strong demand trends for GRAFAPEX following a holiday slowdown, with January 2026 showing one of the strongest months of patient demand since launch [2][3][6] Financial Performance - Total net revenue for Q3 2026 was $25.3 million, a decrease from $30.0 million in the same quarter last year, attributed to reduced sales of Rupall and the return of Gleolan [5][14][16] - Gross profit was reported at $13.6 million, with a gross margin improvement to 53.6% from 50.7% year-over-year [15] - Operating cash flow for Q3 2026 was $7.8 million, an increase from $6.7 million in the prior year [19] GRAFAPEX Launch and Demand - GRAFAPEX product-level revenue for the nine-month period ended December 31, 2025, was $8.2 million, compared to $8.5 million invested in launch-related personnel and infrastructure [1][6] - Management expects GRAFAPEX to generate product-level net revenue of $11 million to $12 million for fiscal year 2026 [1][6] - As of the report, 32% of 180 U.S. transplant centers had ordered GRAFAPEX, with 77% of those reordering, indicating strong adoption [4][7] Reimbursement and Adoption Dynamics - Reimbursement for GRAFAPEX is characterized as "excellent," with Medicare NTAP potentially covering up to approximately $21,000 for about 30% of adult patients [4][11] - Management noted that transplant activity is concentrated among a subset of centers, with the top 76 centers performing about 80% of transplants, where GRAFAPEX penetration is stronger [8][11] Cash Flow and Debt Management - Cash on hand was reported at $15.0 million as of December 31, 2025, down from $24.0 million at March 31, 2025, while net debt decreased to $10.4 million [20][21] - The company entered a new senior secured credit agreement, reducing quarterly principal repayments to $0.5 million from $3.3 million under the previous facility [21][22] Portfolio Updates - Management provided updates on other products, noting a 17% increase in patient unit demand for Rasuvo due to competitive changes, while Rupall continues to face generic competition [18]